Long-acting preparations of exenatide

References

• Khafagy el-S Morishita M Onuki Y Takayama K Current challenges in non-invasive insulin delivery systems: a comparative review Adv Drug Deliv Rev 2007 59 15 1521 1546 17881081
   PubMed Web of Science ®Google Scholar
• Jin Y Song YP Zhu X Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport Biomaterials 2012 33 5 1573 1582 22093292
   PubMed Web of Science ®Google Scholar
• Kendall DM Riddle MC Rosenstock J Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea Diabetes Care 2005 28 9 1083 1091 15855571
   PubMed Web of Science ®Google Scholar
• McGarry JD Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes Diabetes 2002 51 1 7 18 11756317
   PubMed Web of Science ®Google Scholar
• Pories WJ Albrecht RJ Etiology of type II diabetes mellitus: role of the foregut World J Surg 2001 25 4 527 531 11344408
   PubMed Web of Science ®Google Scholar
• Cvetkovic′ RS Plosker GL Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea) Drugs 2007 67 6 935 954 17428109
   PubMed Web of Science ®Google Scholar
• Triplitt C Chiquette E Exenatide: from the Gila monster to the pharmacy J Am Pharm Assoc (2003) 2006 46 1 44 55 16529340
   PubMed Web of Science ®Google Scholar
• Gentilella R Bianchi C Rossi A Rotella CM Exenatide: a review from pharmacology to clinical practice Diabetes Obes Metab 2009 11 6 544 556 19383034
   PubMed Web of Science ®Google Scholar
• Eng J Kleinman WA Singh L Singh G Raufman JP Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas J Biol Chem 1992 267 11 7402 7405 1313797
   PubMed Web of Science ®Google Scholar
• Cure P Pileggi A Alejandro R Exenatide and rare adverse events N Engl J Med 2008 358 18 1969 1972 18450614
   PubMed Web of Science ®Google Scholar
• Nielsen LL Young AA Parkes DG Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes Regul Pept 2004 117 2 77 88 14700743
   PubMedGoogle Scholar
• Kolterman OG Buse JB Fineman MS Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes J Clin Endocrinol Metab 2003 88 7 3082 3089 12843147
   PubMed Web of Science ®Google Scholar
• Painter NA Morello CM Singh RF McBane SE An evidence-based and practical approach to using Bydureon™ in patients with type 2 diabetes J Am Board Fam Med 2013 26 2 203 210 23471935
   PubMed Web of Science ®Google Scholar
• Xiao L Chen Q Bao Y Pan F Release pattern improvement of nomegestrol from biodegradable microspheres by using polymer-alloys as matrix Asian J Pharm Sci 2010 5 6 231 238
   Google Scholar
• Jeyanthi R Mehta RC Thanoo BC DeLuca PP Effect of processing parameters on the properties of peptide-containing PLGA microspheres J Microencapsul 1997 14 2 163 174 9132468
   PubMed Web of Science ®Google Scholar
• Nikou KN Stivaktakis N Avgoustakis K A HER-2/neu peptide admixed with PLA microspheres induces a Th1-biased immune response in mice Biochim Biophys Acta 2005 1725 2 182 189 16126344
   PubMed Web of Science ®Google Scholar
• Wright SG Christenson T Yeah TYinventors Alkermes Inc, assignee Polymer-based sustained release device United States patent US7456254 B2 11 1 2008
   Google Scholar
• Li X Li L Wang X Ren Y Zhou T Lu W Application of model-based methods to characterize exenatide-loaded double-walled microspheres: in vivo release, pharmacokinetic/pharmacodynamic model, and in vitro and in vivo correlation J Pharm Sci 2012 101 10 3946 3961 22753275
   PubMed Web of Science ®Google Scholar
• DeYoung MB MacConell L Sarin V Trautmann M Herbert P Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes Diabetes Technol Ther 2011 13 11 1145 1154 21751887
   PubMed Web of Science ®Google Scholar
• Drucker DJ Buse JB Taylor K Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study Lancet 2008 372 9645 1240 1250 18782641
   PubMed Web of Science ®Google Scholar
• Norwood P Liutkus JF Haber H Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years Clin Ther 2012 34 10 2082 2090 23031623
   PubMed Web of Science ®Google Scholar
• Wysham C Grimm M Chen S Once weekly exenatide: efficacy, tolerability and place in therapy Diabetes Obes Metab 2 20 2013
   Web of Science ®Google Scholar
• Malone J Trautmann M Wilhelm K Exenatide once weekly for the treatment of type 2 diabetes Expert Opin Investig Drugs 2009 18 3 359 367
   PubMed Web of Science ®Google Scholar
• Murphy CE Review of the safety and efficacy of exenatide once weekly for the treatment of type 2 diabetes mellitus Ann Pharmacother 2012 46 6 812 821 22669803
   PubMed Web of Science ®Google Scholar
• Ridge T Moretto T Macconell L Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes Diabetes Obes Metab 2012 14 12 1097 1103
   PubMed Web of Science ®Google Scholar
• Wang J Wang BM Schwendeman SP Characterization of the initial burst release of a model peptide from poly (D, L-lactide-co-glycolide) microspheres J Control Release 2002 82 2 289 307 12175744
   PubMed Web of Science ®Google Scholar
• Cleland JL Solvent evaporation processes for the production of controlled release biodegradable microsphere formulations for therapeutics and vaccines Biotechnol Progr 1998 14 1 102 107
   Web of Science ®Google Scholar
• Shi L Liu B Wang M Effect of molecular weight of poly(Lactic-co-Glycolide) on properties of exenatide-loaded microspheres China Modern Medicine 2009 7 117 118
   Google Scholar
• Kwak HH Shim WS Hwang S Pharmacokinetics and efficacy of a biweekly dosage formulation of exenatide in Zucker diabetic fatty (ZDF) rats Pharm Res 2009 26 11 2504 2512 19756973
   PubMed Web of Science ®Google Scholar
• Liu B Dong Q Wang M Preparation, characterization, and pharmacodynamics of exenatide-loaded poly(DL-lactic-co-glycolic acid) microspheres Chem Pharm Bull (Tokyo) 2010 58 11 1474 1479 21048339
   PubMed Web of Science ®Google Scholar
• Kim H Park H Lee J Highly porous large poly(lactic-co-glycolic acid) microspheres adsorbed with palmityl-acylated exendin-4 as a long-acting inhalation system for treating diabetes Biomaterials 2011 32 6 1685 1693 21126761
   PubMed Web of Science ®Google Scholar
• Yang HJ Park IS Na K Biocompatible microspheres based on acetylated polysaccharide prepared from water-in-oil-in-water (W1/O/W2) double-emulsion method for delivery of type II diabetic drug (exenatide) Colloids Surf A 2009 340 1–3 115 120
   Web of Science ®Google Scholar
• Hiemstra C Zhou W Zhong Z Wouters M Feijen J Rapidly in situ forming biodegradable robust hydrogels by combining stereocomplexation and photopolymerization J Am Chem Soc 2007 129 32 9918 9926 17645336
   PubMed Web of Science ®Google Scholar
• Vermonden T Censi R Hennink WE Hydrogels for protein delivery Chem Rev 2012 112 5 2853 2888 22360637
   PubMed Web of Science ®Google Scholar
• Anderson JM Rodriguez A Chang DT Foreign body reaction to biomaterials Semin Immunol 2008 20 2 86 100 18162407
   PubMed Web of Science ®Google Scholar
• Li K Yu L Liu X Chen C Chen Q Ding J A long-acting formulation of a polypeptide drug exenatide in treatment of diabetes using an injectable block copolymer hydrogel Biomaterials 2013 34 11 2834 2842 23352120
   PubMed Web of Science ®Google Scholar
• Joabsson FC Johnsson MC Tiberg FCinventors Camurus AB Goddard Capplicants GLP-1 analogue formulations European patent EP1888031 A1 2 20 2008
   Google Scholar
• Leitch JW Gillis AM Wyse DG Reduction in defibrillator shocks with an implantable device combining antitachycardia pacing and shock therapy J Am Coll Cardiol 1991 18 1 145 151 2050917
   PubMed Web of Science ®Google Scholar
• Wilkins E Atanasov P Muggenburg BA Integrated implantable device for long-term glucose monitoring Biosensors and Bioelectronics 1995 10 5 485 494 7786472
   PubMed Web of Science ®Google Scholar
• Kuzma P Decker S Quandt Hinventors Endo Pharmaceuticals Solutions Inc, assignee Sustained delivery of exenatide and other peptides United State patent US 20100292144 A1 11 18 2010
   Google Scholar
• Khandare J Minko T Polymer–drug conjugates: progress in polymeric prodrugs Prog Polym Sci 2006 31 4 359 397
   Web of Science ®Google Scholar
• Laman AG Shepelyakovskaya AO Boziev KhM Structural modification effects on bioactivities of the novel 15-mer peptide adjuvant Vaccine 2011 29 44 7779 7784 21871941
   PubMed Web of Science ®Google Scholar
• Rolin B Larsen MO Gotfredsen CF The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice Am J Physiol Endocrinol Metab 2002 283 4 E745 E752 12217892
   PubMed Web of Science ®Google Scholar
• Pan CQ Buxton JM Yung SL Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist J Biol Chem 2006 281 18 12506 12515 16505481
   PubMed Web of Science ®Google Scholar
• Dhalluin C Ross A Leuthold LA Structural and biophysical characterization of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers Bioconjug Chem 2005 16 3 504 517 15898716
   PubMed Web of Science ®Google Scholar
• Kochendoerfer G Chemical and biological properties of polymer-modified proteins Expert Opin Biol Ther 2003 3 8 1253 1261 14640951
   PubMed Web of Science ®Google Scholar
• Park EJ Tak TH Na DH Lee KC Effect of PEGylation on stability of peptide in poly(lactide-co-glycolide) microspheres Arch Pharm Res 2010 33 7 1111 1116 20661722
   PubMed Web of Science ®Google Scholar
• Veronese FM Pasut G PEGylation, successful approach to drug delivery Drug Discov Today 2005 10 21 1451 1458 16243265
   PubMed Web of Science ®Google Scholar
• Bendele A Seely J Richey C Sennello G Shopp G Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins Toxicol Sci 1998 42 2 152 157 9579027
   PubMed Web of Science ®Google Scholar
• Gong N Ma AN Zhang LJ Site-specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity Brit J Pharmacol 2011 163 2 399 412 21244372
   PubMed Web of Science ®Google Scholar
• Hansen TK Lau Jinventors Novo Nordisk A/Sassignee Protracted exendin-4 compounds United States patent US20110301084 A1 12 8 2011
   Google Scholar
• Schellenberger V Wang CW Geething NC A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner Nat Biotechnol 2009 27 12 1186 1190 19915550
   PubMed Web of Science ®Google Scholar
• Kong JH Oh EJ Chae SY Lee KC Hahn SK Long acting hyaluronate – exendin 4 conjugate for the treatment of type 2 diabetes Biomaterials 2010 31 14 4121 4128 20149450
   PubMed Web of Science ®Google Scholar
• Chae SY Jin CH Shin JH Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs J Control Release 2010 142 2 206 213 19900495
   PubMed Web of Science ®Google Scholar
• Chae SY Choi YG Son S Jung SY Lee DS Lee KC The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics J Control Release 2010 144 1 10 16 20093159
   PubMed Web of Science ®Google Scholar
• Lee J Lee C Kim I Preparation and evaluation of palmitic acid-conjugated exendin-4 with delayed absorption and prolonged circulation for longer hypoglycemia Int J Pharm 2012 424 1–2 50 57 22226877
   PubMed Web of Science ®Google Scholar
• Agu RU Ugwoke MI Armand M Kinget R Verbeke N The lung as a route for systemic delivery of therapeutic proteins and peptides Respir Res 2001 2 4 198 209 11686885
   PubMed Web of Science ®Google Scholar
• Patton JS Fishburn CS Weers JG The lungs as a portal of entry for systemic drug delivery Proc Am Thorac Soc 2004 1 4 338 344 16113455
   PubMedGoogle Scholar
• Kim H Lee J Kim TH Albumin-coated porous hollow poly(lactic-co-glycolic acid) microparticles bound with palmityl-acylated exendin-4 as a long-acting inhalation delivery system for the treatment of diabetes Pharm Res 2011 28 8 2008 2019 21472489
   PubMed Web of Science ®Google Scholar
• Andersen C Lorenzen G Arent N Thorengaard B Wittorff Hinventors and assignees Compressed chewing gum tablet United States patent US20100255063 A1 10 7 2010
   Google Scholar
• Kim PH Lee M Kim SW Delivery of two-step transcription amplification exendin-4 plasmid system with arginine-grafted bioreducible polymer in type 2 diabetes animal model J Control Release 2012 162 1 9 18 22705459
   PubMed Web of Science ®Google Scholar
• Léger R Thibaudeau K Robitaille M Identification of CJC-1131-albumin bioconjugate as a stable and bioactive GLP-1(7–36) analog Bioorg Med Chem Lett 2004 14 17 4395 4398 15357960
   PubMed Web of Science ®Google Scholar
• Amiram M Luginbuhl KM Li X Feinglos MN Chilkoti A Injectable protease-operated depots of glucagon-like peptide-1 provide extended and tunable glucose control Proc Natl Acad Sci U S A 2013 110 8 2792 2797 23359691
   PubMed Web of Science ®Google Scholar
• Buse JB Rosenstock J Sesti G LEAD-6 Study Group Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) Lancet 2009 374 9683 39 47 19515413
   PubMed Web of Science ®Google Scholar
• Agersø H Jensen LB Elbrønd B Rolan P Zdravkovic M The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men Diabetologia 2002 45 2 195 202 11935150
   PubMed Web of Science ®Google Scholar